Stomach Cancer Treatment Market to be dominated by Immunotherapy type through 2028
Growing prevalence of stomach cancer is expected to drive the
growth of global stomach cancer treatment in the forecast period, 2024-2028.
According to TechSci Research report, “Stomach Cancer Treatment Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”,
the global stomach cancer treatment market
is anticipated to grow at an impressive rate in the forecast period, 2024-2028.
This can be ascribed to unhealthy lifestyle changes which also incorporates
smoking and alcoholism, etc., globally. Additionally, growing number of cancer
treatments centers with successful treatment plans, especially in the developed
countries in North America and Europe, are expected to create lucrative
opportunities for the market growth in coming years. Besides, increasing
research and development activities on cancer is further expected to support
the market growth. Similarly, growing approval and subsequent launches of new
drugs will further boost the market growth during the forecast period. Also,
rapid adoption of advanced diagnostic tools for the early detection of stomach
cancer is expected to create a significant growth during the forecast period.
Additionally, many pharmaceutical companies are investing for research and
development of novel drugs for the treatment of novel drugs and many
biosimilars of trastuzumab are entering the market which will further boost the
market growth during the forecast period.
However, high cancer
therapy cost and less commercial availability of drugs for the treatment of
stomach cancer may slow down the growth of global stomach cancer treatment market
in the forecast period. Similarly, high risks and complications associated with
cancer therapy and treatments, may hamper the global stomach cancer therapy
treatment market growth during the forecast period. Also, poor reimbursement
scenario and lack of insurance coverage for cancer therapy in emerging
countries, can further restrict the growth of global stomach cancer treatment market.
Similarly, lesser adoption of targeted therapy because of high costs may hamper
the growth of the global stomach cancer treatment market during the forecast
period.
Browse over XX market data Figures
spread through 110
Pages and an in-depth TOC on "Stomach Cancer Treatment Market"
The global stomach
cancer treatment market can be
segmented by treatment type, by cancer type, by route of administration, by
drug class, by distribution channel and by region.
Based on treatment type, the global stomach
cancer treatment market can be segmented into Immunotherapy, Targeted Therapy,
Chemotherapy, Radiation Therapy, Others.
The immunotherapy segment dominated the market in 2022 and is expected to
continue maintaining its dominance throughout the forecast period. This can be
ascribed to increasing product launches and new therapies along with growing advancement
in cancer treatment such as the development of new radiation therapies for the
treatment.
Based on distribution channel, the market can
be segmented into Hospital Pharmacies, Specialty Pharmacies, Others. The hospital pharmacies segment is expected
to dominate during the forecast period on account of increasing number of
patient suffering from stomach cancer in the developing countries.
Major companies operating in global stomach cancer treatment market are:
- Pfizer, Inc.
- Novartis International AG
- Eli Lilly and Company
- Bristol Myers Squibb Company
- Teva Pharmaceutical Industries
AG
- F. Hoffmann La Roche AG
- Mylan N.V.
- Celltrion Healthcare Co., Ltd
- Merck & Co., Inc.
- Teva Pharmaceutical Industries
Ltd.
For instance, in April 2021, the FDA approved
Opdivo for the initial treatment of patients with metastatic or advanced
GC/GEJC. In January 2021, FDA approved Enhertu, an antibody-drug conjugate
product for treating HER-2 positive metastatic gastric cancers.
For instance, in August 2019, Taiho Pharmaceutical
Co., Ltd. obtained additional indication of unresectable advanced or recurrent
gastric cancer that has progressed after chemotherapy for its anticancer agent
LONSURF which is an oral anticancer drug used as a combination of trifluridine
(antineoplastic nucleoside analogue) and tipiracil (a thymidine phosphorylase
inhibitor), from the Japanese Ministry of Health, Labor and Welfare.
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“North America is
expected to dominate in the global stomach cancer treatment market due to increasing
investments in developing advanced treatment options for cancer among the
population, . Furthermore, increasing target patient population with untreated
diseases, along with different cancer types like stomach cancer are further
contributing towards rising stomach cancer treatment demands. Besides, the
growing prevalence of adenocarcinoma, lymphoma and gastrointestinal stromal
tumors across the globe, the launch of novel therapies for metastatic stomach
cancer, availability of skilled professionals and early adoption of advanced
treatments for the treatment of stomach cancer in the region is further
expected to create lucrative opportunities for the market growth” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Stomach
Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028F Segmented By Treatment
Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy,
Others), By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s
Gastrointestinal Stromal Tumors), By Route of Administration (Oral v/s
Injectables), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2
Antagonists, Others), By Distribution Channel (Hospital Pharmacies, Specialty
Pharmacies, Others), By
Region and Competition”, has evaluated
the future growth potential of global stomach cancer treatment market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global stomach
cancer treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com